These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

825 related articles for article (PubMed ID: 19884523)

  • 1. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
    Baccarani M; Cortes J; Pane F; Niederwieser D; Saglio G; Apperley J; Cervantes F; Deininger M; Gratwohl A; Guilhot F; Hochhaus A; Horowitz M; Hughes T; Kantarjian H; Larson R; Radich J; Simonsson B; Silver RT; Goldman J; Hehlmann R;
    J Clin Oncol; 2009 Dec; 27(35):6041-51. PubMed ID: 19884523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial treatment for patients with CML.
    Goldman JM
    Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
    Jabbour E; Cortes JE; Kantarjian HM
    Mayo Clin Proc; 2009 Feb; 84(2):161-9. PubMed ID: 19181650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
    Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
    Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib.
    Olshen A; Tang M; Cortes J; Gonen M; Hughes T; Branford S; Quintás-Cardama A; Michor F
    Haematologica; 2014 Nov; 99(11):1701-9. PubMed ID: 25216683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
    Baccarani M; Deininger MW; Rosti G; Hochhaus A; Soverini S; Apperley JF; Cervantes F; Clark RE; Cortes JE; Guilhot F; Hjorth-Hansen H; Hughes TP; Kantarjian HM; Kim DW; Larson RA; Lipton JH; Mahon FX; Martinelli G; Mayer J; Müller MC; Niederwieser D; Pane F; Radich JP; Rousselot P; Saglio G; Saußele S; Schiffer C; Silver R; Simonsson B; Steegmann JL; Goldman JM; Hehlmann R
    Blood; 2013 Aug; 122(6):872-84. PubMed ID: 23803709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is imatinib-resistant chronic myeloid leukemia? Identifying and managing loss of response.
    Zeidan A; Wang ES; Wetzler M
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):673-83. PubMed ID: 18827790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.
    Jabbour E; Kantarjian H
    Am J Hematol; 2012 Nov; 87(11):1037-45. PubMed ID: 23090888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chronic myeloid leukemia 2008].
    Cervantes F
    Med Clin (Barc); 2008 Nov; 131(17):658-9. PubMed ID: 19087793
    [No Abstract]   [Full Text] [Related]  

  • 10. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
    Baccarani M; Saglio G; Goldman J; Hochhaus A; Simonsson B; Appelbaum F; Apperley J; Cervantes F; Cortes J; Deininger M; Gratwohl A; Guilhot F; Horowitz M; Hughes T; Kantarjian H; Larson R; Niederwieser D; Silver R; Hehlmann R;
    Blood; 2006 Sep; 108(6):1809-20. PubMed ID: 16709930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib: is it all in the dose?
    Condorelli F; Genazzani AA
    BioDrugs; 2010 Jun; 24(3):157-63. PubMed ID: 20222756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current therapy of chronic myeloid leukemia].
    Koskela H; Koskenvesa P; Mustjoki S; Porkka K
    Duodecim; 2012; 128(6):579-88. PubMed ID: 22506320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
    Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
    Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chronic myeloid leukemia. Diagnostics, therapy and future strategy].
    Burchert A; Neubauer A
    Internist (Berl); 2011 Mar; 52(3):283-93; quiz 294-5. PubMed ID: 21253680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of response to imatinib: mechanisms and management.
    Shah NP
    Hematology Am Soc Hematol Educ Program; 2005; ():183-7. PubMed ID: 16304378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.
    Zonder JA; Schiffer CA
    Curr Hematol Malig Rep; 2006 Sep; 1(3):141-51. PubMed ID: 20425345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
    Jabbour E; Kantarjian H; Cortes J
    Semin Hematol; 2010 Oct; 47(4):344-53. PubMed ID: 20875551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the European LeukemiaNet recommendations for the management of CML.
    Baccarani M; Castagnetti F; Gugliotta G; Rosti G
    Ann Hematol; 2015 Apr; 94 Suppl 2():S141-7. PubMed ID: 25814080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.